Your browser doesn't support javascript.
loading
Nurse empowerment through Pharmacogenetics.
Moraes, Jordana Carvalhaes de; Nunes, Fernanda Daniela Dornelas; Coeli-Lacchini, Fernanda Borchers; Miyazaki, Anderson Heiji Lima; Flória-Santos, Milena; Lacchini, Riccardo.
Afiliação
  • Moraes JC; Hospital das Clínicas de Ribeirão Preto, Ribeirão Preto, SP, Brazil.
  • Nunes FDD; Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
  • Coeli-Lacchini FB; Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
  • Miyazaki AHL; GASEO Medicina Ocupacional, Ribeirão Preto, SP, Brazil.
  • Flória-Santos M; Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
  • Lacchini R; Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
Rev Lat Am Enfermagem ; 28: e3265, 2020.
Article em Pt, Es, En | MEDLINE | ID: mdl-32813781
ABSTRACT

OBJECTIVE:

to verify the existence of elements that justify the use of pharmacogenetics by the Brazilian nurse.

METHOD:

this is a quantitative, cross-sectional, observational, descriptive study, whose final sample was 67 individuals. The participants were healthy at the time of the study and reported a history of previous use and the occurrence of adverse effects by drugs commonly used and metabolized by CYP2C9. We collected 4 mL of venous blood for subsequent DNA extraction by salting out method and genotyping of the CYP2C9*2 and CYP2C9*3 polymorphisms, using Polymerase Chain Reaction in real time using Taqman assays.

RESULTS:

the use of drugs metabolized by CYP2C9 was frequent (more than 75% of the individuals have already used between 2 or 4 of these drugs). Regarding adverse events, there were 19 perceived symptomatic occurrences associated with drugs metabolized by CYP2C9. The allele frequency of the polymorphism * 2 and * 3 in the population studied was 11.1% and 7.5%, respectively, and there was a coincidence between the presence of alleles of low enzyme activity and the occurrence of adverse effects.

CONCLUSION:

there are elements that justify the adoption of pharmacogenetics in the nursing care to reduce the occurrence of adverse reactions to drugs metabolized by CYP2C9.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Farmacogenética / Hidrocarboneto de Aril Hidroxilases Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans País como assunto: America do sul / Brasil Idioma: En / Es / Pt Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Farmacogenética / Hidrocarboneto de Aril Hidroxilases Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans País como assunto: America do sul / Brasil Idioma: En / Es / Pt Ano de publicação: 2020 Tipo de documento: Article